Journals
Publish with us
Publishing partnerships
About us
Blog
Case Reports in Oncological Medicine
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Case Reports in Oncological Medicine
/
2020
/
Article
/
Tab 1
/
Case Report
Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
Table 1
Contribution ratio of CYP3A4 to clearance of EGFR-TKIs after oral absorption (CR
CYP3A4
).
Calculated CR
CYP3A4
Standard inhibitor
AUC fold change by standard inhibitor
Reference
Gefitinib
0.46
Itraconazole
1.78
[
13
]
Erlotinib
0.40
Ketoconazole
1.68
[
14
]
Afatinib
0
Osimertinib
0.20
Itraconazole
1.24
[
15
]
IR
CYP3A4
values for itraconazole and ketoconazole are 0.95 and 1.00, respectively (Ref. [
5
]).
Substrate for the P-glycoprotein (P-gp). Metabolism by cytochrome P-450 is of negligible (Ref. [
16
]).